Search Results
Sep 02, 2026, 16:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
Jul 29, 2026, 16:05 ET Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SAN DIEGO, July 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
More news about: Viking Therapeutics, Inc.
Jul 23, 2026, 07:05 ET Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
SAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the
More news about: Viking Therapeutics, Inc.
Jul 22, 2026, 16:05 ET Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
Jul 21, 2026, 16:41 ET Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and
More news about: Kuehn Law, PLLC
Jul 21, 2026, 09:00 ET A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
(Nasdaq: VRTX), Eledon Pharmaceuticals (Nasdaq: ELDN), Sernova Biotherapeutics (OTC: SEOVF), and Viking Therapeutics (Nasdaq: VKTX) all advancing programs across the diabetes and metabolic landscape.A Critical Piece of the Puzzle Falls Into Place
More news about: American News Group
Jul 15, 2026, 08:45 ET As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
computational capability into clinical assets, the same transition MindWalk is positioning its HYFT platform to make.Viking Therapeutics (Nasdaq: VKTX) is not an AI company, but it sits squarely on the demand wave MindWalk is aiming at. Viking is one of the most closely watched names in GLP-1
More news about: Equity Insider
Jun 24, 2026, 07:05 ET Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the
More news about: Viking Therapeutics, Inc.
Jun 11, 2026, 07:05 ET Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the
More news about: Viking Therapeutics, Inc.
May 21, 2026, 07:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
May 12, 2026, 07:05 ET Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
SAN DIEGO, May 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today presented additional
More news about: Viking Therapeutics, Inc.
May 05, 2026, 07:05 ET Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that
More news about: Viking Therapeutics, Inc.
Apr 29, 2026, 16:05 ET Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
More news about: Viking Therapeutics, Inc.
Apr 22, 2026, 16:35 ET Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
Apr 10, 2026, 07:30 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
Mar 26, 2026, 07:05 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the
More news about: Viking Therapeutics, Inc.
Mar 05, 2026, 16:03 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
Feb 13, 2026, 11:26 ET Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
Sciences (CSE: MOOD), Amneal Pharmaceuticals (NASDAQ: AMRX), Prestige Consumer Healthcare (NYSE: PBH), Viking Therapeutics (NASDAQ: VKTX), and Insulet (NASDAQ: PODD).
More news about: Equity Insider
Feb 11, 2026, 16:16 ET Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its
More news about: Viking Therapeutics, Inc.
Feb 04, 2026, 16:05 ET Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the
More news about: Viking Therapeutics, Inc.
Jan 08, 2026, 07:00 ET Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the
More news about: Viking Therapeutics, Inc.
Jan 07, 2026, 07:00 ET Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the
More news about: Viking Therapeutics, Inc.
Jan 05, 2026, 16:03 ET Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that
More news about: Viking Therapeutics, Inc.
Dec 31, 2025, 08:07 ET The End of Shots? 5 Biotech Stocks Rethinking Diabetes
(OTCQB: AVAI), Novo Nordisk A/S (NYSE: NVO), Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), Viking Therapeutics, Inc. (NASDAQ: VKTX), and Tandem Diabetes Care, Inc. (NASDAQ: TNDM).
More news about: USA News Group